On April 6, 2026 Vyome Holdings, Inc. ("Vyome") (Nasdaq: HIND) reported that the company will present its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for malodor and other symptoms of Malignant Fungating Wounds ("MFW") at the 2026 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place on April 17-22, 2026, in San Diego.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Venkat Nelabhotla, CEO of Vyome, stated that, "There are currently no FDA approved drugs to treat malodor and other symptoms of MFW. We plan to have FDA interactions in Q2 2026 on the pivotal study design. Recent third-party analysts estimated the total addressable U.S. market to be approximately USD 2.2 billion. Inflammation is one of the biggest healthcare problems facing the world today."
The research will be presented at the session "Phase II and Phase III Clinical Trials in Progress." Vyome will highlight mechanistic insights together with detailed clinical data comparing the VT-1953 active treatment with vehicle treatment in a Phase 2 study. VT-1953 is a first-in-class treatment for malodor and other symptoms of MFW in advanced cancer patients, which acts by a dual mechanism of action, inhibiting DNA Gyr and modulating MD2/TLR interactions, an inflammatory signal. MFW is a rare, debilitating condition that occurs in ~10% of advanced cancer patients, severely impacting the quality of life.
"We are delighted that AACR (Free AACR Whitepaper) found our data compelling for presentation at the annual meeting. Based on our promising clinical data underpinned by strong mechanistic alignment, we are advancing VT-1953 into pivotal studies," said Shiladitya Sengupta, Associate Professor of Medicine at Harvard Medical School, Co-founder and Board member of Vyome.
The details of the presentation at the 2026 AACR (Free AACR Whitepaper) Annual Meeting are:
American Association for Cancer Research Annual Meeting 2026, San Diego
Date: April 21, 2026, 9:00 AM – 12:00 PM
Session title: (PO.CTP01.03) Phase II and Phase III Clinical Trials in Progress
Presentation number and title: CT208 / 3 – Final results from a phase 2 trial testing safety and efficacy of VT-1953 topical gel in patients with malodorous malignant fungating wound
Authors: Arshit Narang, MBBS, Prashant Prakash Lad, MD, Shiladitya Sengupta PhD
(Press release, Vyome Therapeutics, APR 6, 2026, View Source [SID1234664191])